New antibody shows promise in early cancer trial
NCT ID NCT05501821
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new drug called KBA1412, a lab-made antibody that targets a protein on cancer cells. It was given alone or with another cancer drug (pembrolizumab) to 16 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and see if the drug could shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR MALIGNANCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dutch Cancer Institute AVL
Amsterdam, 1066 CX, Netherlands
-
Erasmus Medical Center Rotterdam
Rotterdam, 3015 GD, Netherlands
-
University Hospital Antwerp
Antwerp, 2650, Belgium
-
University Hospital Ghent
Ghent, 9000, Belgium
-
University Hospital Leiden (LUMC)
Leiden, 2333 ZA, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.